AURA

Aura Biosciences, Inc.

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Holles Natalie C.Director, Officer: See Remarks
$16M2.2M shares
Grant / ExerciseMay 19, 2026
$16.0M2.2M shares
$7.39
--
Holles Natalie C.Director, Officer: See Remarks
--600.1k shares
Grant / ExerciseMay 19, 2026
Disclosure amount unavailable600.1k shares
--
--
Holles Natalie C.Director, Officer: See Remarks
--1.2M shares
Grant / ExerciseMay 19, 2026
Disclosure amount unavailable553.8k shares
--
--
Matrix Capital Management Company, LP10 Percent Owner
$06.9M shares
SellMay 7, 2026
$39.0M6.9M shares
$5.64
--
Kilroy ConorSee Remarks
$1.5M217.8k shares
SellApr 16, 2026
$82.4K11.7k shares
$7.02
--
de los Pinos ElisabetDirector, Officer: See Remarks
$1.5M249k shares
Grant / ExerciseMar 2, 2026
$1.5M249k shares
$6.14
--

News

globenewswire.comAura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanomaglobenewswire.comJun 1marketbeat.comAura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advancesmarketbeat.comMay 27marketbeat.comAura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Datamarketbeat.comMay 19globenewswire.comAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 19globenewswire.comAura Biosciences to Participate in Upcoming Investor Conferencesglobenewswire.comMay 12